Stool DNA-Based Colorectal Cancer Detection: Finding the Needle in the Haystack -- At...

Page 1 of 5

JNCI Journal of the National Cancer Institute

Oxford Journals Medicine JNCI J Natl Cancer Inst Volume 93, Number 11 Pp. 798-799
JNCI Journal of the National Cancer Institute 2001 93(11):798-799; doi:10.1093/jnci/93.11.798 2001 by Oxford University Press Journal of the National Cancer Institute, Vol. 93, No. 11, 798-799, June 6, 2001 2001 Oxford University Press

This Article
Extract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted

EDITORIAL Stool DNADNA-Based Colorectal Cancer Detection: Finding the Needle in the Haystack
Wendy Atkin, John P. Martin

Services
Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions

Affiliation of authors: Imperial Cancer Research Fund (ICRF)

Colorectal Cancer Unit, St. Mark's Hospital, Harrow, Middlesex, U.K.

Google Scholar
Articles by Atkin, W. Articles by Martin, J. P. Search for Related Content

Correspondence to: Wendy Atkin, M.P.H., Ph.D., ICRF Colorectal

Cancer Unit, St. Mark's Hospital, Northwick Park, Watford Rd., Harrow, Middlesex, HA1 3UJ, U.K. (e-mail: atkin@icrf.icnet.uk ).

PubMed

For many centuries, it has been suspected that PubMed Citation Articles by Atkin, W. examination of stool could provide insights into the Articles by Martin, J. P. state of health or disease of an individual. The Egyptians were concerned with the shape and consistency of stool (Eber's papyrus, 207), and 19th century Americans were concerned with "poisons and gases" (1); more recently, the components of stool (e.g., pathogens, occult blood, fats, and bile acids) have been the subject of scrutiny. Within the past two decades, with the advent of the polymerase chain reaction (PCR) technique, came the ability to amplify tiny numbers of specific DNA sequences. This advance has permitted the identification of not only mutations that accumulate in neoplasms and define their progression to malignancy but also mutations in cells shed from the tumors into stool. Compared with tissue and blood, extraction of DNA from stool presents special problems because human DNA is often degraded and food digestion products and bacterial contaminants inhibit the PCR. As reported in this issue of the Journal, Dong et al. (2) achieved their goal of extracting sufficient high-quality DNA from all of 51 stool samples collected from patients with a diagnosis of colorectal cancer to permit detection of most mutations

http://jnci.oxfordjournals.org/cgi/content/full/93/11/798

11/13/2007

Stool DNA-Based Colorectal Cancer Detection: Finding the Needle in the Haystack -- At... Page 2 of 5

where they existed in the tumor. This meticulous study focused on mutations in the KRAS oncogene and the TP53 tumor suppressor gene (each of which is mutated in around 40%60% of colorectal cancers) as well as the microsatellite instability (MSI) marker BAT26 (which is altered in 15% of sporadic cancers). Dong et al. were able to detect TP53 and BAT26 mutations in stools from all of the patients with these mutations in their tumor; in each case, the mutation in the stool was identical to that in the tumor, confirming its origin. It was possible to identify K-RAS mutations in only eight of 17 stool samples from patients with a K-RAS mutation in their tumor. The three markers together detected 36 (71%) of the 51 cases of colorectal cancer, but TP53 alone detected 30 of these cases. How do these results compare with those from previous studies, and what does this study tell us about the suitability of these markers for colorectal cancer screening? A consistent finding is that the quantity and quality of the DNA extracted from stools are superior in the presence of colorectal neoplasia (3), probably because there is less efficient degradation by apoptosis of cells shed by tumors compared with fully differentiated cells. Indeed, the amount of extracted DNA per gram of stool has been used as a marker of the presence of malignancy (4). Only one study (5) has reported successful DNA extraction from 100% of stool samples from people with endoscopically normal colons. Providing an informative negative result is an essential component of screening and is possible only if DNA can be extracted from all stool samples. When Sidransky et al. (6) first showed that the mutations in cells shed from K-RASmutated colorectal cancers are detectable in stool, K-RAS appeared to be an ideal candidate for colorectal cancer screening because most mutations are clustered at codons 12 and 13. However, from the outset, K-RAS has been problematic as a marker. Few studies (69) have shown complete sensitivity of K-RAS mutations for colorectal cancer; moreover, K-RAS mutations have been found in up to 14% of stool samples from people with normal colons (3,5,10), a false-positive rate that would be unacceptable in a screening situation. It is not clear if the finding of K-RAS mutations in stools in the absence of neoplasia has any prognostic significance, although in one study (11) K-RAS mutations were detected in colonic effluent samples from two of five patients with previously resected carcinoma and from one patient 4 years before colorectal cancer was diagnosed. Most of the mutations in the TP53 gene found in colorectal tumors can be detected by analysis of exons 58. These exons were analyzed by Dong et al. (2), who found that all patients with mutations in their tumors at these hotspots had identical mutations in their stool samples. BAT26 is a highly sensitive marker of MSI (12), which is a feature of 30%40% of cancers that develop in the colon proximal to the splenic flexure (13,14). MSI is rarely found in sporadic distal colon cancer. In the only other study to have examined BAT26 in stool (5), the marker was positive in five of 10 proximal cancers and in none of 12 distal cancers. In the study by Dong et al. (2), three (23%) of 13 right-sided tumors and their corresponding stools harbored BAT26 mutations. However two (4%) of the

http://jnci.oxfordjournals.org/cgi/content/full/93/11/798

11/13/2007

Stool DNA-Based Colorectal Cancer Detection: Finding the Needle in the Haystack -- At... Page 3 of 5

51 patients in the study had a germline mutation in BAT26, suggesting that this marker may lack specificity. Inherited polymorphisms in BAT26 and BAT25, an alternative marker of MSI, have been found in 8%12% of African-Americans, although only 3% showed variation in both markers (15,16). These polymorphisms were found in only 0.1% of Caucasians (15,16), but it is important to know the extent to which they affect other populations because those with substantial rates would require additional markers to confirm that the instability is confined to the tumor. Dong et al. (2) have shown that a small panel of genetic markers might potentially detect 70% of colorectal cancers. They advise caution, however, in interpreting this finding as evidence to support the application of molecular screening for the early detection of colorectal cancer because most of the cancers were advanced and the patients were symptomatic. Ideally, colorectal screening should aim to detect the disease in the premalignant phase to avoid the morbidity associated with surgery. Previous data (5) have shown that TP53 and BAT26 have no role in the detection of adenomas (except perhaps in those with severe dysplasia) and that K-RAS lacks specificity. Detection in stool of mutations in APC, a gene mutated early in the development of adenomas, or of strands of DNA longer than 200 base pairs (L-DNA), a marker of repressed apoptosis, may be of more value than the markers studied by Dong et al. for the detection of adenomas because together these markers detected 73% of adenomas 1 cm or larger (5). Future studies should focus on the ability of genetic markers in stool to identify cancers and adenomas with high malignant potential in a screening setting. In addition, now that it has been shown that adequate DNA can be efficiently extracted from stool to detect tumor-derived mutations, this field is open for creative minds to think of new markers. Detecting mutations in the genes classically associated with the adenoma-tocarcinoma sequence is now possible but laborious. Identifying markers of the resulting abnormalities in neoplasia, as exemplified by L-DNA and instability in BAT26, may provide a more efficient approach.

REFERENCES
1 Jamison A. Intestinal ills. New York (NY): Tyrell's Hygienic Institute; 1918. 2 Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001;93:85865.[Abstract/Free Full Text] 3 Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, et al. Identification of subjects at risk for colorectal carcinoma through a test based on Kras determination in the stool. Gastroenterology 1996;110:134653.[CrossRef][ISI] [Medline]cancerlit;96200518 4 Loktionov A, O'Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R. Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998;4:337 42.[Abstract]cancerlit;98177564 5 Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE,

http://jnci.oxfordjournals.org/cgi/content/full/93/11/798

11/13/2007

Stool DNA-Based Colorectal Cancer Detection: Finding the Needle in the Haystack -- At... Page 4 of 5

et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000;119:121927. [CrossRef][ISI][Medline]cancerlit;20509958 6 Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:1025.[Abstract/Free Full Text]cancerlit;92229409 7 Smith-Ravin J, England J, Talbot IC, Bodmer W. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995;36:816. [Abstract/Free Full Text]cancerlit;95197084 8 Ratto C, Flamini G, Sofo L, Nucera P, Ippoliti M, Curigliano G, et al. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum 1996;39:123844.[CrossRef][ISI][Medline]cancerlit;97076115 9 Hasegawa Y, Takeda S, Ichii S, Koizumi K, Maruyama M, Fujii A, et al. Detection of K-ras mutations in DNAs isolated from feces of patients with colorectal tumors by mutant-allele-specific amplification (MASA). Oncogene 1995;10:14415.[ISI] [Medline]cancerlit;95249255 10 Nollau P, Moser C, Weinland G, Wagener C. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR. Int J Cancer 1996;66:332 6.[CrossRef][ISI][Medline]cancerlit;96198640 11 Tobi M, Luo FC, Ronai Z. Detection of K-ras mutation in colonic effluent samples from patients without evidence of colorectal carcinoma. J Natl Cancer Inst 1994;86:100710.[Abstract/Free Full Text]cancerlit;94275886 12 Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997;57:3003.[Abstract/Free Full Text]cancerlit;97153282 13 Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol 1994;145:14856.[Abstract]cancerlit;94303786 14 Chao A, Gilliland F, Willman C, Joste N, Chen IM, Stone N, et al. Patient and tumor characteristics of colon cancers with microsatellite instability: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:53944. [Abstract/Free Full Text]cancerlit;20324537 15 Pyatt R, Chadwick RB, Johnson CK, Adebamowo C, de la Chapelle A, Prior TW. Polymorphic variation at the BAT-25 and BAT-26 loci in individuals of African origin. Implications for microsatellite instability testing. Am J Pathol 1999;155:34953. [Abstract/Free Full Text]cancerlit;99364922 16 Samowitz WS, Slattery ML, Potter JD, Leppert MF. BAT-26 and BAT-40 instability in colorectal adenomas and carcinomas and germline polymorphisms. Am J Pathol 1999;154:163741.[Abstract/Free Full Text]cancerlit;99293008

http://jnci.oxfordjournals.org/cgi/content/full/93/11/798

11/13/2007

Stool DNA-Based Colorectal Cancer Detection: Finding the Needle in the Haystack -- At... Page 5 of 5

This Article
Extract FREE Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted

Services
Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions

Google Scholar
Articles by Atkin, W. Articles by Martin, J. P. Search for Related Content

PubMed
PubMed Citation Articles by Atkin, W. Articles by Martin, J. P.

Online ISSN 1460-2105 - Print ISSN 0027-8874 Copyright 2007 Oxford University Press Oxford Journals Oxford University Press Site Map Privacy Policy Frequently Asked Questions Other Oxford University Press sites: Oxford University Press

http://jnci.oxfordjournals.org/cgi/content/full/93/11/798

11/13/2007